

KEY CORPORATE INFORMATION

ASX CODE: TIS

DIRECTORS:

Roger Clarke (Chairman)
Neil Reinhardt
Prof. David Gardiner
Greg Baynton (Executive Director)

Scientific Advisor: Prof. Rob Baxter
Chief Executive Officer: Dr Steven Mercer
Chief Scientific Officer: Assoc. Prof. Zee Upton

ISSUED CAPITAL:

15,455,000 Ordinary Shares
1,115,000 Options

SUBSTANTIAL SHAREHOLDERS:

QUT	14.59%	
Prof. Zee Upton		8.61%
Acorn Capital	6.47%	

Top 20 Shareholders hold: 55.84%

CORPORATE STRATEGY:

Tissue Therapies is an Australian biomedical company with exclusive international technology rights in wound care and other skin treatments, including cosmetics, tissue regeneration and cell culture. Its core technology platform, VitroGro®, is a novel biological formulation for enhancing cell growth and migration.

VitroGro® has applications in accelerated and scar-less wound healing with or without harvesting cells from other parts of the patient's body to 'seed' the wound site with new cells, among other applications.

In recent pre-clinical trials, VitroGro® has demonstrated accelerated cell growth and tissue regeneration alone and in combination with other wound care technologies, medical devices and implants.

The VitroGro® technology was invented by leading tissue engineering experts at QUT.

**MAJOR PRODUCT MILESTONE
ACHIEVED – SYNTHETIC VITROGRO®**

SUMMARY

Low-cost Synthetic Vitronectin sources proven

- Tissue Therapies has confirmed that it now has multiple sources of synthetic (recombinant) vitronectin – a key human protein within its VitroGro® wound care and cell culture technology.
- All of these sources of synthetic vitronectin are now confirmed as biologically-active and are available at a fraction of the current world price of human-derived vitronectin.
- These low-cost sources of synthetic vitronectin complete the final step in producing a totally synthetic VitroGro® product and an approved clinical product for use in humans.

Other Recent Product Development Milestones

- Early this month, the Company announced that its product development efforts have delivered a new advanced form of VitroGro® in a powdered form, achieved through a freeze-drying process (lyophilisation).
- Along with the safety benefits and cost savings of synthetic VitroGro® components, the new powdered VitroGro® product enables significantly more flexible distribution alternatives for global markets, and progresses further towards a product for use in humans.

Full details of this announcement are provided on the following page.

More information: www.tissuetherapies.com



26 October 2005

MAJOR PRODUCT MILESTONE ACHIEVED – SYNTHETIC VITROGRO®

Biomedical company, **Tissue Therapies Limited (ASX: TIS)** today announced it has achieved another important milestone towards delivering a low-cost wound healing and skin regeneration product for human use.

The Company has confirmed it now has multiple sources of synthetic, or recombinant, vitronectin for use in its advanced VitroGro® products.

Tissue Therapies Managing Director, Dr Steven Mercer said that developing synthetic vitronectin was an important milestone in delivering the Company's advanced VitroGro® wound healing, skin regeneration and cell culture products to clinical markets in the future.

"Our research team at QUT has confirmed that each of these sources of synthetic vitronectin are biologically-active," he said.

"This now allows us to replace the human-derived vitronectin previously used in VitroGro®, with synthetic vitronectin, eliminating any risk of cross-infection from human blood products."

Vitronectin, a key component of the patented VitroGro® technology, is a 'sticky' protein present in human and animal blood serum that promotes the adhesion and spreading of cells.

The Company's 2003 IPO Prospectus foreshadowed the development of synthetic VitroGro® and identified synthetic vitronectin as an important ingredient in future VitroGro® products that provide alternatives to animal and human-derived products.

Dr Mercer said that a further benefit of these synthetic vitronectin sources is that they are available at a fraction of the current world price of human-derived vitronectin, significantly reducing the production costs of VitroGro®.

"These low-cost sources of synthetic vitronectin complete the final step in developing a totally synthetic VitroGro® product, an essential prerequisite for an approved clinical product for use in human wound healing and skin regeneration," Dr Mercer said.

Early this month, Tissue Therapies announced that its product development efforts have delivered a new advanced form of VitroGro® in a powdered form, achieved through a freeze-drying process (lyophilisation).

The new powdered VitroGro® product enables significantly more flexible distribution alternatives for global markets, and simplifies the product enormously.

The achievement of a synthetic and powdered form of VitroGro® removes further major constraints on achieving a clinically used product and global product distribution and significantly lowers production and distribution costs.

Tissue Therapies has worldwide exclusive rights to commercialise the VitroGro® wound healing technology, developed by Tissue Engineering experts at QUT.

ENDS

Further information or for an interview:

Dr Steven Mercer, CEO, Tissue Therapies Limited
Telephone: 0417 483 834